Research
Energy balance
Participants receiving tirzepatide maintained a mean weight change of -5.5% from week 36 to week 88 compared to a 14.0% weight change with placebo (difference, -19.4%; P < .001).
Continued use of tirzepatide is effective for maintaining weight loss in adults with obesity.
StrongSupportsmedium confidence
The mean percent weight change from week 36 to week 88 was -5.5% with tirzepatide vs 14.0% with placebo (difference, -19.4% [95% CI, -21.2% to -17.7%]; P < .001).
Why this rating
Based on study design from abstract.
Source
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity
Louis J. Aronne et al. · JAMA · 2023
rct · n=783Cited 679×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →